Pfizer Shares Hit 52-Week High as Drugmakers Rally
Pfizer shares reached $29.88 Thursday, clearing the previous 52-week peak of $29.21, as drugmakers rose broadly. The FDA approved a Tukysa regimen on Oct. 7.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
For best results when printing this announcement, please click on link below: Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026 Data from 57 abstracts will highlight Pfizer’s scientific progress targeting infectious diseases, including pneumococcal disease and RSV Pfizer Inc. ( ) (NYSE: P
Pfizer to Present Infectious Disease Data at IDWeek 2026
Pfizer says it will present data from more than 50 research abstracts at the October 21-24 congress in Washington, D.C.